Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer

Journal of Negative Results in BioMedicine

Volumn 11, Issue 1, 2012, Pages

  Vlachostergios, Panagiotis J ^a   Karasavvidou, Foteini ^a   Kakkas, Grigorios ^a   Kapatou, Kassiani ^a   Gioulbasanis, Ioannis ^a   Daliani, Danai D ^a   Moutzouris, George ^a   Papandreou, Christos N ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN P16; PROTEIN P27; ANDROGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE SECTION; ADENOCARCINOMA; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; ANDROGENS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84855397487     PISSN: None     EISSN: 14775751     Source Type: Journal    
DOI: 10.1186/1477-5751-11-2     Document Type: Article

References (35)

1. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Hunter T, Pines J, Cell 1994 79 573 582 10.1016/0092-8674(94)90543-6 7954824 (Pubitemid 24363801)
2. Principles of CDK regulation. Morgan DO, Nature 1995 374 131 134 10.1038/374131a0 7877684
3. Inhibitors of mammalian G1 cyclin-dependent kinases. Sherr CJ, Roberts JM, Genes Dev 1995 9 1149 1163 10.1101/gad.9.10.1149 7758941
4. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Serrano M, Hannon GJ, Beach D, Nature 1993 366 704 707 10.1038/366704a0 8259215 (Pubitemid 24036021)
5. A cell cycle regulator potentially involved in genesis of many tumor types. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH, Science 1994 264 436 440 10.1126/science.8153634 8153634
6. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Lee CT, Capodieci P, Osman I, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C, Clin Cancer Res 1999 5 977 983 10353729 (Pubitemid 29233210)
7. Expression of p 16 protein in prostatic adenocarcinomas, intraepithelial neoplasia, and benign/hyperplastic glands. Halvorsen OJ, Haukaas S, Høisæter PA, Akslen LA, Urol Oncol 1997 3 59 66 10.1016/S1078-1439(97)00038-0 21227061 (Pubitemid 27469237)
8. The p16INK4a/CDKN2A tumor suppressor and its relatives. Ruas M, Peters G, Biochim Biophys Acta 1998 1378 115 177 9823374
9. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Zhang Z, Rosen DG, Yao JL, Huang J, Liu J, Mod Pathol 2006 19 1339 1343 10.1038/modpathol.3800655 16799475 (Pubitemid 44423081)
10. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, Lee YY, Bartram CR, Koeffle HP, Cancer Res 1995 55 2266 2269 7757974
11. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Guo Y, Sklar GN, Borkowski A, Kyprianou N, Clin Cancer Res 1997 3 2269 2274 9815624 (Pubitemid 28133145)
12. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI, J Natl Cancer Inst 1998 90 1284 1291 10.1093/jnci/90.17.1284 9731735 (Pubitemid 28433473)
13. Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. Fernández PL, Arce Y, Farré X, Martínez A, Nadal A, Rey MJ, Peirá N, Campo E, Cardesa A, J Pathol 1999 187 563 566 10.1002/(SICI)1096-9896(199904)187:5<563::AID-PATH292>3.0.CO;2-3 10398122 (Pubitemid 29151998)
14. Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression. Jiang H, Chou HS, Zhu L, Mol Cell Biol 1998 18 5284 5290 9710613 (Pubitemid 28388112)
15. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Matsuda Y, Ichida T, Genda T, Yamagiwa S, Aoyagi Y, Asakura H, Clin Cancer Res 2003 9 3389 3396 12960127 (Pubitemid 37082734)
16. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI, J Natl Cancer Inst 1999 91 1869 1876 10.1093/jnci/91.21.1869 10547394
17. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R, Scand J Urol Nephrol Suppl 2005 216 34 63 16019758
18. Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Osman I, Yee H, Taneja SS, Levinson B, Zeleniuch-Jacquotte A, Chang C, Nobert C, Nanus DM, Clin Cancer Res 2004 10 4096 4100 10.1158/1078-0432.CCR-04-0120 15217945 (Pubitemid 38812488)
19. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Halvorsen OJ, Høstmark J, Haukaas S, Høisaeter PA, Akslen LA, Cancer 2000 88 416 424 10.1002/(SICI)1097-0142(20000115)88:2<416:: AID-CNCR24>3.0.CO;2-# 10640976 (Pubitemid 30051828)
20. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL, Clin Cancer Res 2001 7 544 550 11297246 (Pubitemid 32707976)
21. Expression of p27kip1 in prostatic adenocarcinoma. Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG, Lohse CM, Wollan P, Mod Pathol 1998 11 324 328 9578081
22. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Erdamar S, Yang G, Harper JW, Lu X, Kattan MW, Thompson TC, Wheeler TM, Mod Pathol 1999 12 751 755 10463475 (Pubitemid 29383876)
23. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM, Cancer Res 1998 58 542 548 9458103 (Pubitemid 28087420)
24. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE, J Urol 1998 159 941 945 10.1016/S0022-5347(01)63776-5 9474188 (Pubitemid 28106561)
25. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Kuczyk M, Machtens S, Hradil K, Schubach J, Christian W, Knüchel R, Hartmann J, Bokemeyer C, Jonas U, Serth J, Br J Cancer 1999 81 1052 1058 10.1038/sj.bjc.6690806 10576664 (Pubitemid 29516151)
26. Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer. Kuczyk MA, Bokemeyer C, Hartmann J, Schubach J, Walter C, Machtens S, Knuchel R, Kollmannsberger C, Jonas U, Serth J, Oncol Rep 2001 8 1401 1407 11605074 (Pubitemid 33758755)
27. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, Lieskovosky G, J Natl Cancer Inst 1998 90 916 920 10.1093/jnci/90.12.916 9637141 (Pubitemid 28304160)
28. Low p27 expression predicts biochemical relapse after radical prostatectomy in patients with clinically localised prostate cancer. Ribal MJ, Fernandez PL, Lopez-Guillermo A, Farré X, Santos Y, Gibanel R, Cardesa A, Alcaraz A, Anticancer Res 2003 23 5101 5106 14981973 (Pubitemid 38182131)
29. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Halvorsen OJ, Haukaas SA, Akslen LA, Clin Cancer Res 2003 9 1474 1479 12684422 (Pubitemid 36418404)
30. Expression of p27(Kip1), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells. Nikoleishvili D, Pertia A, Trsintsadze O, Gogokhia N, Managadze L, Chkhotua A, Int Urol Nephrol 2008 40 953 959 10.1007/s11255-008-9350-y 18317945
31. Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Dreher T, Zentgraf H, Abel U, Kappeler A, Michel MS, Bleyl U, Grobholz R, Virchows Arch 2004 444 509 517 15118854 (Pubitemid 38858374)
32. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Drobnjak M, Melamed J, Taneja S, Melzer K, Wieczorek R, Levinson B, Zeleniuch-Jacquotte A, Polsky D, Ferrara J, Perez-Soler R, Cordon-Cardo C, Pagano M, Osman I, Clin Cancer Res 2003 9 2613 2619 12855638 (Pubitemid 36842104)
33. Immunohistochemistry expression of tumor markers CD34 and P27 as a prognostic factor of clinically localized prostate adenocarcinoma after radical prostatectomy. Nassif AE, Tmbara Filho R, Rev Col Bras Cir 2010 37 338 344 21180999
34. Role of p21(WAF1) and p27(KIP1) in predicting biochemical recurrence for organ-confined prostate adenocarcinoma. Wu TT, Wang JS, Jiaan BP, Yu CC, Tsai JY, Lin JT, Huang JK, J Chin Med Assoc 2007 70 11 15 10.1016/S1726-4901(09) 70294-1 17276927 (Pubitemid 46218237)
35. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Tenta R, Koutsilieris M, In Vivo 2005 19 911 920 16097446 (Pubitemid 41065152)